SIRT2 and Burkitt lymphoma: With selective SIRT2 inhibitors in hand, we proceeded to evaluate cytotoxicity of our compounds in Daudi, Raji (Burkitt lymphoma) and OCI-Ly8-LAM-53 (OCI, a representative of several Diffuse Large B-Cell Lymphoma lines; DLBCL) cell lines.